Meeting
2022 ASCO Annual Meeting
Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study.
Authors
Aung Naing
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Aung Naing , Hirva Mamdani , Minal A. Barve , Melissa Lynne Johnson , Daniel Morgensztern , Anthony J. Olszanski , Robert A. Wolff , Shubham Pant , Marya F. Chaney , Tolani Adebanjo , Jean Fan , Richard D. Kim , Scott Kopetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT04332653
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2514)
DOI
10.1200/JCO.2022.40.16_suppl.2514
Abstract #
2514
Poster Bd #
170
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok
Poster
2022 ASCO Annual Meeting
Cisplatin (Cis) combined with sintilimab (Sint) and niraparib (Nir) in advanced solid tumors: Updated results.
First Author: TAO Haitao